Why did Veracyte (VCYT) stock move recently?

On 8/25/2026, Veracyte moved +6.2% — VCYT rose on a technical rebound from a sharp recent sell-off (down ~25% over the past month) amid positive analyst sentiment and upward earnings estimate revisions, with no new company-specific catalyst reported today. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Veracyte (VCYT) overvalued or fairly valued?

MarketChacha shows Veracyte's valuation in context — a trailing P/E of about 47.8, a forward P/E of about 21.8, a price-to-book of about 2.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Veracyte's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (15.89×) from reported figures — education, not a rating.

What is Veracyte's revenue?

Veracyte reported revenue of $517.1M for FY2025, with net profit of $66.4M, per official filings.

What is the share price of Veracyte (VCYT)?

Veracyte last traded at $42.53 (-5.2% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Veracyte

VCYT · NYSE · Healthcare · United States

Snapshot

TickerVCYT

ExchangeNYSE

SectorHealthcare

IndustryDiagnostics & Research

CountryUnited States

Employees755

HeadquartersSouth San Francisco, United States

Websitewww.veracyte.com

Filings tracked13

About Veracyte

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Who owns it

Insiders0.5%
Institutions99.5%
Public & other0.0%

512 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.16.78%
FMR, LLC9.58%
Artisan Partners Limited Partnership6.89%
Vanguard Portfolio Management LLC5.87%
State Street Corporation5.84%
Vanguard Capital Management LLC4.47%
Dimensional Fund Advisors LP3.52%
First Trust Advisors LP3.12%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of 5.1% is on the low side — the business earns a modest return on shareholder capital.

Cash conversion15.89×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend-20.6% → 12.8%

Margin has expanded by about 33.4 points — the business is getting more profitable.

Return on equity5.1%

Latest ROE of 5.1% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $157.3M · EPS 0.45

Est. earnings growth -15.3%

Next fiscal year

Rev $659.9M · EPS 1.95

Est. earnings growth +2.2%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$517.1M

Net margin

12.8%

ROE

5.1%

Revenue CAGR (2y)

+19.7%

EPS (FY2025)

0.82

Net profit (FY2025)

$66.4M

Ask MarketChacha about VCYT

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 25, 2026
VCYT rose on a technical rebound from a sharp recent sell-off (down ~25% over the past month) amid positive analyst sentiment and upward earnings estimate revisions, with no new company-specific catalyst reported today.
source 1 ↗source 2 ↗· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$517.1M	$66.4M	0.82	12.8%	5.1%
FY2024	$445.8M	$24.1M	0.31	5.4%	2.1%
FY2023	$361.1M	$-74.4M	-1.02	-20.6%	-7.1%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$150.3M	$25.5M	0.31	17.0%
2026Q1	$139.1M	$28.7M	0.35	20.6%
2025Q3	$131.9M	$19.1M	0.24	14.5%
2025Q2	$130.2M	$-980,000	-0.01	-0.8%
2025Q1	$114.5M	$7.0M	0.09	6.2%
2024Q3	$115.9M	$15.2M	0.19	13.1%
2024Q2	$114.4M	$5.7M	0.07	5.0%
2024Q1	$96.8M	$-1.9M	-0.02	-1.9%
2023Q3	$90.1M	$-29.6M	-0.41	-32.9%
2023Q2	$90.3M	$-8.4M	-0.12	-9.3%
2023Q1	$82.4M	$-8.1M	-0.11	-9.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC7/31/2026
8-K — Results of operations, Exhibits
SEC7/30/2026material
8-K — Executive/director change, Shareholder vote results
SEC6/11/2026material
10-Q filing
SEC5/6/2026
8-K — Results of operations, Exhibits
SEC5/5/2026material
8-K — Executive/director change
SEC3/16/2026material
10-K filing
SEC2/26/2026
8-K — Results of operations, Exhibits
SEC2/25/2026material
8-K — Results of operations, Exhibits
SEC1/12/2026material

2025

10-Q filing
SEC11/5/2025
8-K — Results of operations, Exhibits
SEC11/4/2025material
10-Q filing
SEC8/7/2025
8-K — Results of operations, Exhibits
SEC8/6/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.